|
|
|
[3的CRT vs RFA]
肺癌射频消融：三维适形放疗 vs 射频消融
日期：2020-03-03 16:52:09
点击：64
好评：0
Medically Inoperable Stage I NSCLC: RF Ablation vs 3D-CRT Treatment, study, year Survival 1yr 2yr 3yr RF Ablation, RAPTUREclincal trial 2007 Overall survival 71% NA Cancer-specific survival 92% 92% NA 3D-CRT, Bradley et al, IJROBP 2003 Ove...
[不同治疗方式选择的比较]
肺癌不同治疗模式生存比较
日期：2020-03-02 23:57:26
点击：74
好评：0
Alla Y. Zemlyak, MD Comparison of survival after sublobar resections and ablative therapies for stage I NSCLC Primary end points overall survival, cancer-specific survival, and cancer-free survival N=25 SLR N=12 RFA N=27 Cryo N= CECT, FDG...
[分期]
肺癌射频消融：分期比较
日期：2020-03-02 23:38:12
点击：146
好评：0
RF Ablation of Medically Inoperable Stage I NSCLC Simon et al, Radiology 2007...
[3cm≤大小＞3cm]
肺癌疗效比较：3cm
日期：2020-03-01 22:57:39
点击：94
好评：0
RFA - Local efficacy Median time to local tumor progression Simon CJ et al., Pulmonary Radiofrequency Ablation: Long-Term Safety and Efficacy in 153 Patients 2007, Radiology...
[1和II期高危患者比较]
I和II期高危NSCLC治疗比较
日期：2020-02-28 22:05:24
点击：194
好评：2
RF Ablation Results: Comparative Therapies High-risk stage 1 and 2 NSCLC Modality 1-year 2-year 3-year 5-year LC DM Zemlyaketal SLR(25) 87.1% 12% 12% 3-ycancer-specific 90.6%,87.5%,90.2% 3-ycancer-free(p0.05) 60.8%,50%,45.6% RFA(12) 87.5%...
[I 期 NSCLC]
早期NSCLC治疗方式的比较
日期：2020-02-28 21:32:58
点击：86
好评：0
RF Ablation Results: Comparative Therapies M odality 5-yearsurvival StageINSCLC LocalRecurrence (mostwithin2years) Lobarresection 60-80% 能手术尽手术 6.4% Sub-lobarresection 60-70% 17.2% Image-guidedablation 27% 22.2%1 Externalbeamradiatio...
[I期 NSCLC]
I期 NSCLC 射频消融结果
日期：2020-02-28 21:23:38
点击：66
好评：0
RF Ablation Results Pulmonary RFA: Long-term safety and efficacy in 153 patients1 - Local control group (n = 132) - 71 patients with stage I NSCLC - Overall survival rates: stage I NSCLC 78% 57% 36% 27% 27% 1-year 2-year 3-year 4-year 5-ye...
[RAPTURE]
Rapture Trial
日期：2020-02-27 21:21:31
点击：100
好评：0
R adiofrequency A blation of P ulmonary TU mors R esponse E valuation ( RAPTURE) Trial Riccardo Lencioni, MD, Pisa, Italy Lencioni et al. Lancet Oncol 2008; 9:621-628. NSCLC (n = 33) CRC (n = 53) Other (n = 20) Total (n = 106) Gender (F :...
RF Ablation Results: Comparative Therapies High-risk stage 1 and 2 NSCLC Modalit...